Eric Jonasch
Overview
Explore the profile of Eric Jonasch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
248
Citations
10391
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Jonasch E, Song Y, Freimark J, Berman R, Nguyen H, Signorovitch J, et al.
Orphanet J Rare Dis
. 2024 Feb;
19(1):73.
PMID: 38365728
Background: To date, real-world evidence around the clinical and economic burden related to von Hippel-Lindau (VHL) disease is limited. Therefore, this study characterized the prevalence, healthcare resource utilization (HRU), and...
12.
Hahn A, Surasi D, Viscuse P, Bathala T, Wiele A, Campbell M, et al.
Oncologist
. 2023 Nov;
29(5):392-399.
PMID: 38035767
Background: Metastatic RCC with sarcomatoid and/or rhabdoid (S/R) dedifferentiation is an aggressive disease associated with improved response to immune checkpoint therapy (ICT). The outcomes of patients treated with VEGFR-targeted therapies...
13.
Jonasch E, Bauer T, Papadopoulos K, Plimack E, Merchan J, Mcdermott D, et al.
Eur J Cancer
. 2023 Nov;
196:113434.
PMID: 38008031
Background: Accumulation of the HIF-2α transcription factor is an oncogenic event implicated in the tumorigenesis of clear cell renal cell carcinoma (ccRCC). In the phase I LITESPARK-001 study, the first-in-class...
14.
Liu X, Zhang Y, McGrail D, Zhang X, Lam T, Hoang A, et al.
Clin Cancer Res
. 2023 Aug;
29(19):4002-4015.
PMID: 37527013
Purpose: Immune checkpoint blockade (ICB) demonstrates durable clinical benefits in a minority of patients with renal cell carcinoma (RCC). We aimed to identify the molecular features that determine the response...
15.
Perelli L, Carbone F, Zhang L, Huang J, Le C, Khan H, et al.
Nat Cancer
. 2023 Jun;
4(7):984-1000.
PMID: 37365326
Molecular routes to metastatic dissemination are critical determinants of aggressive cancers. Through in vivo CRISPR-Cas9 genome editing, we generated somatic mosaic genetically engineered models that faithfully recapitulate metastatic renal tumors....
16.
Hasanov E, Jonasch E
Hematol Oncol Clin North Am
. 2023 Jun;
37(5):1005-1014.
PMID: 37270383
The development of brain metastases is a poor prognostic indicator in renal cell carcinoma. Regular imaging and clinical examinations are necessary to monitor the brain before or during systemic therapy....
17.
Shapiro D, Zacharias N, Tripathi D, Karki M, Bertocchio J, Soeung M, et al.
Clin Transl Med
. 2023 May;
13(5):e1267.
PMID: 37226898
Background: Renal medullary carcinoma (RMC) is a highly aggressive cancer in need of new therapeutic strategies. The neddylation pathway can protect cells from DNA damage induced by the platinum-based chemotherapy...
18.
Ko S, Lee W, Weigert M, Jonasch E, Lengyel E, Naora H
J Extracell Vesicles
. 2023 Mar;
12(4):e12318.
PMID: 36973758
Extracellular vesicles (EVs) are ideal for liquid biopsy, but distinguishing cancer cell-derived EVs and subpopulations of biomarker-containing EVs in body fluids has been challenging. Here, we identified that the glycoproteins...
19.
Hahn A, Kotecha R, Viscuse P, Pieretti A, Wiele A, Jonasch E, et al.
Eur Urol Focus
. 2023 Mar;
9(5):734-741.
PMID: 36863962
Background: Renal cell carcinoma (RCC) with sarcomatoid and/or rhabdoid (S/R) dedifferentiation is a highly aggressive tumor with a poor prognosis. Immune checkpoint therapy (ICT) has shown significant treatment efficacy in...
20.
Gatto F, Bratulic S, Jonasch E, Limeta A, Maccari F, Galeotti F, et al.
JCO Precis Oncol
. 2023 Feb;
7:e2200361.
PMID: 36848607
Purpose: No liquid biomarkers are approved in metastatic renal cell carcinoma (mRCC) despite the need to predict and monitor response noninvasively to tailor treatment choices. Urine and plasma free glycosaminoglycan...